ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
OrganiGram Holdings Inc

OrganiGram Holdings Inc (OGI)

2.53
-0.04
(-1.56%)
Closed September 19 4:12PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.53
Bid
2.53
Ask
2.59
Volume
150,222
2.52 Day's Range 2.63
1.35 52 Week Range 3.95
Market Cap
Previous Close
2.57
Open
2.55
Last Trade
11
@
2.53
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
225,961
Shares Outstanding
81,162,000
Dividend Yield
-
PE Ratio
-0.83
Earnings Per Share (EPS)
-3.06
Revenue
161.64M
Net Profit
-248.6M

About OrganiGram Holdings Inc

Sector
Pharmaceutical Preparations
Industry
Miscellaneous Metal Ores,nec
Headquarters
Moncton, New Brunswick, Can
Founded
2014
OrganiGram Holdings Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker OGI. The last closing price for OrganiGram was $2.57. Over the last year, OrganiGram shares have traded in a share price range of $ 1.35 to $ 3.95.

OrganiGram currently has 81,162,000 shares outstanding. The market capitalization of OrganiGram is $208.59 million. OrganiGram has a price to earnings ratio (PE ratio) of -0.83.

OGI Latest News

Organigram Announces Completion of Share Consolidation

TORONTO, July 05, 2023 (GLOBE NEWSWIRE) -- Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI) announced today that, further to its earlier press releases, it has...

High Tide Becomes Top Revenue-Generating Cannabis Company in Canada

High Tide Becomes Top Revenue-Generating Cannabis Company in Canada PR Newswire CALGARY, AB, Nov. 22, 2022 Data recently released by New Cannabis Ventures shows that the Company is now the...

Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

TORONTO and HERZILA, Israel, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”), a leading Canadian licensed producer of cannabis, and Canndoc...

S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSX

S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSX Canada NewsWire TORONTO, le 3 déc. 2021 TORONTO, le 3 déc. 2021 /CNW/ - À la suite de...

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index Canada NewsWire TORONTO, Dec. 3, 2021 TORONTO, Dec. 3, 2021 /CNW/ - As a result of the quarterly review, S&P Dow...

Organigram Holdings Inc. Files Preliminary Base Shelf Prospectus

Organigram Holdings Inc. Files Preliminary Base Shelf Prospectus Canada NewsWire MONCTON, NB, June 24, 2021 MONCTON, NB, June 24, 2021 /CNW/ - Organigram Holdings Inc. ("Organigram" or...

AgraFlora and Other Owners Agree to Sell Edibles Business for $35 Million to Organigram

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to...

S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSX

S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSX Canada NewsWire TORONTO, le 12 mars 2021 TORONTO, le 12 mars 2021 /CNW/ - À la suite de...

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index Canada NewsWire TORONTO, March 12, 2021 TORONTO, March 12, 2021 /CNW/ - As a result of the quarterly review, S&P...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.041.606425702812.492.722.472218152.53716417CS
4-0.07-2.692307692312.62.792.352182822.53744376CS
120.4823.41463414632.052.841.982259612.42573396CS
26-0.29-10.28368794332.823.951.983394872.69713599CS
520.145.857740585772.393.951.352639012.54145112CS
156-9.47-78.91666666671212.841.355873126.94998234CS
260-19.87-88.705357142922.4321.35112706211.50352034CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SMCSulliden Mining Capital Inc
$ 0.015
(50.00%)
476k
CRWNCrown Capital Partners Inc
$ 1.38
(38.00%)
5.75k
NUMINuminus Wellness Inc
$ 0.035
(16.67%)
89.4k
ASNDAscendant Resources Inc
$ 0.04
(14.29%)
7.4k
BSXBelo Sun Mining Corp
$ 0.04
(14.29%)
1.5k
VRTSVertiqal Studios Corporation
$ 0.01
(-33.33%)
145k
BRYBri Chem Corp
$ 0.255
(-22.73%)
104.12k
RTGRTG Mining Inc
$ 0.035
(-22.22%)
28k
BABYElse Nutrition Holdings Inc
$ 0.03
(-14.29%)
1.04M
THTheratechnologies Inc
$ 1.63
(-13.30%)
89.11k
CNQCanadian Natural Resources Ltd
$ 44.73
(0.11%)
13.29M
FCUFission Uranium Corp
$ 0.84
(3.70%)
7.69M
PPLPembina Pipeline Corporation
$ 54.71
(-1.05%)
7.59M
BCEBCE Inc
$ 48.52
(3.34%)
6.66M
CVECenovus Energy Inc
$ 22.64
(-0.35%)
6.21M

OGI Discussion

View Posts
WALL STREET KID WALL STREET KID 3 weeks ago
Thanks Hunchbackgeek
👍️0
Hunchbackgeek Hunchbackgeek 3 weeks ago
OGI Organigram Reports Third Quarter Fiscal 2024 Results https://www.organigram.ca/organigram-reports-third-quarter-fiscal-2024-results
👍️ 2 👽️ 1 🚀 1
nowwhat2 nowwhat2 1 month ago
One year ago (shares soared) ?




https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=ca%3Aogi&x=0&y=0&time=100&startdate=1%2F4%2F2018&enddate=10%2F30%2F2024&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9
👍️0
john1311 john1311 1 month ago
Thanks, Hunch... excellent news.... favourable financials.... OGI management doing things right... shares up some 24% today.... happy days... bright future... Hunch, you deserve a big smile on your happy face....
👍️ 2 💚 1
Bazwar6 Bazwar6 1 month ago
Wow 25% increase… What a great quarter!

https://www.newcannabisventures.com/organigram-q3-revenue-increases-25/
👍️ 2 🤑 1
WALL STREET KID WALL STREET KID 1 month ago
Thanks bud
👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 1 month ago
Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology
August 7th, 2024 https://www.organigram.ca/press-releases#main-content
👍️ 2 👽️ 1
Hunchbackgeek Hunchbackgeek 1 month ago
Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024

https://www.organigram.ca/organigram-to-report-third-quarter-fiscal-2024-results-on-august-13-2024

👋🙂👍️ Hi John
👍️ 2 😸 1
Bazwar6 Bazwar6 1 month ago
https://financialpost.com/pmn/business-wire-news-releases-pmn/organigram-product-development-collaboration-completes-landmark-clinical-study-on-nanoemulsion-technology
👍️ 1 💚 1
Bazwar6 Bazwar6 2 months ago
https://www.businesswire.com/news/home/20240723136952/en/Organigram-to-Bolster-Auto-Flower-and-Rare-Cannabinoid-Portfolio-with-Partial-Third-Tranche-Investment-of-US-1M-into-Phylos.
👍️ 1 💚 1
Bazwar6 Bazwar6 2 months ago
https://thedalesreport.com/cannabis/organigram-expands-thcv-portfolio-with-phylos-investment/
👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 2 months ago
OGI 🙂 Thanks John
👍️ 2 💚 1 💯 1 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 2 months ago
International Business https://investors.organigram.ca/international

Aligned to its vision, “To be a respected global leader in the emerging cannabis movement”, Organigram is committed to expanding its market presence by adding to its product offering and enhancing its geographical presence. This vision is enabled by strategic merger and acquisition opportunities and assessing expansion into international markets.

Currently, Organigram has 5 international partners who are medical cannabis leaders in their geographies.

CANNDOC*: In June 2020, Organigram entered into a multi-year agreement to supply dried flower to one of Israel’s largest and most established pharmaceutical cannabis producers, Canndoc Ltd., a subsidiary of InterCure Ltd. In November 2022, the companies jointly entered into a new multi-year agreement wherein Organigram will supply up to 20,000 kg of dried flower over multiple years.

CANNATREK*: In May 2018, Organigram entered into agreement with Cannatrek, a fully licenced and proudly Australian vertically integrated medicinal cannabis enterprise to supply medical cannabis products. Organigram currently ships Grade A Indoor, Bulk Cannabis flower to Cannatrek in Australia that is sold under Cannatrek’s brands.

MEDCAN AUSTRALIA*: In August 2022, Organigram signed a new agreement with Medcan Australia, a front runner in the Australia Medicinal Cannabis Industry to supply high quality medical cannabis flower.

Medcan Australia previously had an agreement with Laurentian Organic Inc. prior to Organigram's acquisition of the company.

SANITY GROUP: In May 2023, Organigram entered into a supply agreement for dried flower with the medical division of German cannabis company Sanity Group, a health and life sciences company based in Berlin, Germany, dedicated to the medical applications of cannabinoids. Under the terms of the agreement Organigram will provide high-quality, indoor-grown dried flower product to Sanity Group and grant Sanity Group strain exclusivity on certain genetics.

4C LABS: In August 2023, Organigram further expanded its global footprint by entering into a supply agreement to provide dried Medical Cannabis flower to 4C LABS, a rapidly scaling healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution, and clinical development of cannabis-based products for human health in the United Kingdom. Organigram has been chosen by 4C LABS to be the preferred supplier of Medical Cannabis flower to deliver innovative new products to the UK market and expects to supply approximately 600 kilograms of high-quality, indoor-grown dried flower product within the first year.



*Activities under the Agreement are subject to compliance with all applicable laws, including receipt of all requisite approvals from Health Canada, the Israeli Medical Cannabis Agency (IMCA) the Australian Therapeutic Goods Administration (TGA), and any other applicable regulatory authorities.

Given recent political changes in the United States, Organigram continues to monitor and develop potential U.S. entry strategies that could include THC, CBD and other minor cannabinoids, while also monitoring recreational legalization opportunities in European jurisdictions with a particular focus on German opportunities based on the size of the addressable market and recent regulatory changes.
👍️ 2 💚 1 💯 1 💱 1 💲 1 🚀 1
john1311 john1311 2 months ago
OGI bullish Biden sentiment this morning pre market
👍️ 2 💚 1 💯 1 💱 1 💲 1 🚀 1
WALL STREET KID WALL STREET KID 2 months ago
Thanks Hunchbackgeek
🇮🇩 1 🇮🇴 1 🇹🇹 1
john1311 john1311 2 months ago
This deal with Sanity if good forward thinking... I wonder what is the increase in medical canna customers in Germany since legalisation on April 1...? Does anyone have the figures...?
👍️ 1 💚 1
john1311 john1311 2 months ago
Thanks for that, Hunch.
👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 3 months ago
Organigram Invests in Leading German Cannabis Company Sanity~Group... https://www.organigram.ca/press-releases/organigram-invests-in-sanity-group-a-leading-german-cannabis-company

Organigram Invests in Sanity Group, a Leading German Cannabis Company June 25th, 2024

Second “Jupiter” investment strengthens Organigram’s European access, including to the high-growth market of Germany.

Highlights:

Concurrent to the investment, Organigram and Sanity Group have entered into a new supply agreement to include significantly higher volumes and the intention to work together on the commercialization of Organigram’s brands and intellectual property (IP) in Germany.
Investment in the form of an unsecured convertible note combined with a minority equity stake in Sanity Group. Organigram entitled to appoint a representative to Sanity Group’s Board of Directors.

TORONTO, June 25, 2024 --- Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its first significant strategic investment aimed at expanding its presence in the European cannabis market. Using proceeds from its Jupiter strategic investment pool, the Company has agreed to invest €14 million (~ C$21 million) initially comprised of €11.5 million via an unsecured convertible note and €2.5 million to purchase equity interests from existing Sanity Group founders and shareholders providing the Company with a minority stake in Berlin-based cannabis company Sanity Group GmbH (“Sanity” or “Sanity Group”). In addition, the Company may advance another €3 million (~ C$4.5 million) as a second tranche of the unsecured convertible note for future opportunities to be pursued by Sanity subject to the satisfaction of certain conditions.

Sanity has quickly established itself as a leader in the German cannabis market where it maintains a robust distribution network with over 2,000 pharmacies working with approximately 5,000 physicians in Germany. Sanity currently holds approximately a 10% share of the German medical cannabis market where its medical brand, avaay, is estimated to hold the number two position and has shown impressive revenue growth since the recent legal reforms regarding partial legalization of adult-use recreational cannabis in Germany. Additionally, Sanity is currently participating in a Swiss recreational cannabis pilot program in the Basel canton, with one store operational and a plan to expand its retail footprint in Switzerland. In the coming months, Sanity is expected to invest in proprietary distribution channels providing it with what it believes will be a competitive advantage that capitalizes on new medical consumers entering the market.

The Company's investment also expands the previously announced supply agreement between Organigram and Sanity Group. Until such time as Organigram receives EU-GMP certification at its Moncton production facility, Sanity Group has committed to purchase significantly higher annual volumes of dried flower under the new agreement as compared to the previous one. Once Organigram receives EU-GMP certification in Moncton, Sanity Group will shift its annual purchase commitment from Organigram to a percentage of its overall assortment of flower offerings for the European market. Organigram expects to complete its final EU-GMP audit before the end of the calendar year. Additionally, the new commercial agreement contemplates, subject to terms and conditions, avenues by which Organigram can launch its industry-leading brands, products, and IP in the German market.

“A meaningful presence in Germany and Europe are essential to achieving our ambitions to be a global cannabis leader. We believe that after Canada, Germany will emerge as one of the more promising markets under a nationally legal model,” said Paolo De Luca, Chief Strategy Officer of Organigram. “With its evolving program for medical cannabis and recent limited legalization for recreational consumption, Germany may eventually adopt a full adult-use cannabis framework. This growth opportunity is magnified by positive regulatory developments in several neighbouring European jurisdictions where Sanity Group is expanding its presence,” he concluded.

“Our investment in Sanity Group establishes a significant European footprint for us. Organigram benefits from Sanity’s expertise and insights in the German (and in the future) other European cannabis markets. This has the potential to provide a pathway for us to launch our own brands and industry-leading IP through Sanity’s extensive distribution network. This relationship also bolsters our European revenue generation through a significantly expanded commercial agreement,” said Beena Goldenberg, CEO of Organigram.

“We are extremely pleased to close this strategic financing with Organigram who has consistently demonstrated itself to be a leader in the highly competitive and regulated Canadian cannabis market,” said Finn Hansel, co-founder and CEO of Sanity Group. “With its commitment to responsible R&D, innovation and product development, including through its relationship with BAT (British American Tobacco), we feel that we have chosen a partner that will support us in becoming a leader in the rapidly expanding legal European markets,” he concluded.



The German and European Cannabis Market

The German cannabis industry is poised for significant expansion following the recreational cannabis legal reforms enacted on April 1, 2024. According to BDSA estimates, Germany is expected to bring in ~USD$1.5 billion in total sales in 2024, set to grow to ~USD$3.7 billion by 2027. This remarkable growth is driven by a 30-50% increase in medical cannabis prescriptions since April 1, 2024, a likely result of the regulatory framework changes that may have accelerated the shift by consumers from the illicit market to the legal market. Germany’s cannabis industry progress is also anticipated to create a ‘ripple effect’, potentially shaping economic, regulatory, public health, and cultural landscapes across Europe. The success of Germany's cannabis industry could serve as a catalyst for a more unified and progressive approach to cannabis legalization and regulation across the continent.



Strategic Rationale and Potential Opportunities

Establishes a significant European footprint for Organigram through a leading regional cannabis company with a presence in multiple markets.
Organigram benefits from Sanity’s expertise and insights in the German (and in future) other European cannabis markets.
Provides a pathway for Organigram to launch its own brands and industry-leading IP in Europe through Sanity’s extensive distribution network.
Bolsters Organigram’s European revenue generation through an expanded commercial agreement with improved terms and commitments.
Further investment opportunities may allow Organigram to increase its unsecured convertible note and ownership position in Sanity Group.


Investment Details

€14 million initial investment consists of €11.5 million structured as an unsecured convertible note (the “Note”) issued by Sanity Group to the Company as lender and €2.5 million of already issued equity interests purchased from existing shareholders.
The Note yields 10% annual paid-in-kind (PIK) interest for a minimum of three years and is convertible at a discount to the price established by Sanity Group’s next qualified financing into the most senior class of shares (currently Series B).
Organigram has an option, subject to certain terms and conditions, to invest an additional €3 million on substantially the same terms as the Note which would bring its total investment to €17 million.
Sanity’s use of proceeds includes investments in various initiatives that are expected to give it access to over 100,000 patients, and aid in recreational cannabis pilot project expansion in applicable regions.
Notable previous investors in Sanity Group include BAT, Casa Verde Capital (Snoop Dog), Will.i.am (Black Eyed Peas), Navy Capital, Scooter Braun and Alyssa Milano amongst others.




About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary Organigram Inc. is a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality cannabis for adult recreational consumers, as well as developing international business partnerships to expand the Company’s global footprint. Organigram has also developed and acquired a portfolio of adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates production facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).



About Sanity Group

Berlin-based Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the endocannabinoid system. In addition to pharmaceuticals, the focus is also on wellbeing and cosmetic products that utilize cannabinoids. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (minority investment in finished pharmaceuticals), and VAAY (wellbeing). Close to Frankfurt, Sanity Group also operates a storage facility for cannabis extracts and flower. More information can be found on sanitygroup.com/press.



Forward-Looking Information

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram and Sanity Group to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include applicable regulatory and market conditions in Germany and other European markets in future, the ability to conclude terms related to any future licensing and brand opportunities in Germany, the receipt of any required regulatory and shareholder approvals and consents from time to time and factors and risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

SOURCE: https://www.organigram.ca/press-releases/organigram-invests-in-sanity-group-a-leading-german-cannabis-company

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations

investors@organigram.ca



For Media enquiries:
Megan McCrae, Senior Vice President – Global Brands and Corporate Affairs
megan.mccrae@organigram.ca
👍️ 2 💚 1 💯 1 💱 1 💲 1 🚀 1
Bazwar6 Bazwar6 3 months ago
https://www.coastreporter.net/the-mix/organigram-takes-stake-in-german-cannabis-firm-sanity-group-with-21m-investment-9133134
👍️ 1 💚 1
WALL STREET KID WALL STREET KID 3 months ago
That's awesome thanks HunchbackGeek
👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 3 months ago
OGI OrganiGram Investor Presentation https://www.organigram.ca/investor-presentation
👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 3 months ago
OGI Signs 3-Year Suppy Agreement, Avida UK
Organigram Signs Three Year Supply Agreement with Avida Medical in UK May 28th, 2024
https://www.organigram.ca/organigram-signs-three-year-supply-agreement-with-avida-medical-in-uk

Over a three-year period, Organigram expects to supply 1,700 kilograms of high-quality medical cannabis flower to Avida Medical, with 500 kilograms expected to be delivered in the first year of the agreement.

Avida Medical to become Organigram’s second international medical cannabis customer in the UK.

Organigram to grant Avida Medical strain exclusivity in the UK for three strains.

To date, Organigram has established international supply agreements with a total of seven medical cannabis customers in Australia, Germany, Israel, and the UK, aligned to its strategy to extend its reach beyond Canada into global markets.

Toronto, Ontario, May 28, 2024 – Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business.

Subject to the terms of the Agreement, the Company expects to supply 1,700 kilograms of high-quality, indoor-grown dried cannabis flower to Avida Medical in the UK over a period of three years.

"We are pleased to partner with Avida Medical in the UK, marking yet another exciting milestone for Organigram's expansion into the global market. As frontrunners in the cannabis industry, we recognize the immense potential of the UK market. Our decision to further expand into this market stems from our commitment to ensuring patients have access to reliable, high-quality medical cannabis offerings,” said Tim Emberg, Chief Commercial Officer of Organigram. “With our extensive industry expertise in cultivation and production, we are poised to elevate accessibility and cater to the evolving requirements of patients in the UK. We are confident that this strategic move will not only strengthen our international presence but also reinforces our objective of advancing global access to medical cannabis,” Emberg concluded.

“Our agreement with Organigram exemplifies our commitment to providing the highest quality medicine and service to patients. The UK is home to one of the largest patient populations using medicinal cannabis in Europe, and this is set to grow exponentially over the next four years. As the market matures, it is those producers and manufacturers that have focused on ensuring the highest quality of their products and processes, that will determine the companies that succeed,” commented Paul Parkinson, Chief Executive Officer, Avida Medical.

“This is a hugely positive collaboration for Avida Medical and brings us a step closer to becoming one of the pre-eminent manufacturers of medicinal cannabis products here in the UK,” he added.

FULL NEWS RELEASE HERE: https://www.organigram.ca/organigram-signs-three-year-supply-agreement-with-avida-medical-in-uk
👍️ 2 💚 2 💯 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 3 months ago
Organigram Reports Second Quarter Fiscal 2024 Results https://www.organigram.ca/organigram-reports-second-quarter-fiscal-2024-results May/15/2024

~ 21% growth in recreational net revenue year-over-year
~ First Jupiter private placement tranche closed adding $41.5 million of cash bringing Organigram's closing cash balance at quarter-end to $83.6 million
~ Subsequent to quarter end, closed $28.8 million oversubscribed marketed offering, which when combined with the remaining two anticipated Jupiter tranches
will increase cash position by additional $110 million
~ Company's recent investment in Steady State LLC (d/b/a Open Book Extracts) ("OBX") adds to
growing U.S. portfolio, which includes Phylos Bioscience Inc. ("Phylos")
~ Organigram's U.S.-based strategic investments may benefit from expected change in rescheduling of
cannabis by the Drug Enforcement Administration from
Schedule I to Schedule III

FULL REPORT HERE:
https://www.organigram.ca/organigram-reports-second-quarter-fiscal-2024-results


.
👍️ 1 💚 1
cashbyers cashbyers 3 months ago
on’t overlook this undervalued synergy!

British American Tobacco already has existing deals with both Charlottes Web Holdings $CWBHF and Organigram Holdings $OGI… There are a few possibilities for how BAT could leverage its partnerships with both companies:

Joint Investment: BAT, Charlottes Web, and Organigram could collaborate on a joint venture or even a merger (depending on regulations) to create a larger cannabis and CBD company. This would require significant planning and navigating potential regulatory hurdles.”

Market Expansion: BATs global reach could be valuable for both Charlottes Web and Organigram. BAT could help them enter new markets where cannabis or CBD products are legal. For example, BAT might leverage its existing distribution channels for these products.

Knowledge Sharing: BAT could act as a bridge between the two companies, facilitating knowledge sharing and best practices in areas like marketing, regulatory compliance, and cultivation techniques.
👍️ 1 💚 1
WALL STREET KID WALL STREET KID 4 months ago
Thanks Bud :)
🇮🇩 1 🇮🇴 1 🇹🇹 1 👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 4 months ago
Orginigram Second Quarter Fiscal 2024 Results May/14/2024

Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024
TORONTO—(BUSINESS WIRE)—May 8, 2024—Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2024 ended March 31, 2024, on Tuesday, May 14, 2024, prior to market open.

The Company will host a conference call to discuss its results with details as follows:

Date: Tuesday, May 14, 2024

Time: 8:00 am Eastern Time

To register for the conference call, please use this link:

https://registrations.events/direct/Q4I9676693302

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:

https://events.q4inc.com/attendee/619527249

Participants will receive their details via email.

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.


About Organigram
Organigram is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis- derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Circular, and the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations
investors@organigram.ca

For Media enquiries:

Megan McCrae, Senior Vice President – Marketing and Communications
megan.mccrae@organigram.ca
👍️0
Hunchbackgeek Hunchbackgeek 4 months ago
Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024
TORONTO—(BUSINESS WIRE)—May 8, 2024—Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2024 ended March 31, 2024, on Tuesday, May 14, 2024, prior to market open.

The Company will host a conference call to discuss its results with details as follows:

Date: Tuesday, May 14, 2024

Time: 8:00 am Eastern Time

To register for the conference call, please use this link:

https://registrations.events/direct/Q4I9676693302

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:

https://events.q4inc.com/attendee/619527249

Participants will receive their details via email.

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.


About Organigram
Organigram is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis- derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks disclosed in the Circular, and the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries:

Max Schwartz, Director of Investor Relations
investors@organigram.ca

For Media enquiries:

Megan McCrae, Senior Vice President – Marketing and Communications
megan.mccrae@organigram.ca
👍️0
john1311 john1311 5 months ago
Thanks, Hunch.... this is great news... sounds a winning innovative product... it is just a pity we cannot legally consume high quality milled flower SHRED on this side of the pond... unfortunately Europe, US and much of the world, are so far behind Canada... if the Ottawa government was smart it would reduce the tax burned on LPs to normal, and not unfair draconian as at present, and allow these Canadian legal operators to retain capital and so grow themselves into mammoth international companies, which would be to the ultimate benefit of the Ottawa government, and the Canadian taxpayer.... cheers...
👍️ 1 😎 1
Hunchbackgeek Hunchbackgeek 5 months ago
Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales APRIL 3RD, 2024
https://www.organigram.ca/press-releases/organigrams-popular-shred-brand-surpasses-200-million-in-yearly-retail-sales

😎 Always good to hear from you John.
👍️0
john1311 john1311 5 months ago
Thanks for that, Hunch... now I understand market movement from that... OGI share price ought to be way better than it is today.... but then again, so should peace on earth...
👍️ 2 💚 2 💱 1 💲 1 🚀 1
WALL STREET KID WALL STREET KID 6 months ago
Thanks HBG
🇮🇩 1 🇮🇴 1 🇹🇹 1 👍️ 1 💚 1
Hunchbackgeek Hunchbackgeek 6 months ago
OGI~Organigram Announces Pricing of Overnight Marketed Public Offering ~ March 27th, 2024
https://www.organigram.ca/press-releases/organigram-announces-pricing-of-overnight-marketed-public-offering
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 6 months ago
OGI~Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment ~ MARCH 26TH, 2024
https://www.organigram.ca/press-releases/organigram-invests-in-us-based-open-book-extracts-representing-inaugural-jupiter
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 6 months ago
OGI~Organigram Receives Health Canada’s Final Redetermination on Jolts ~ March 25th, 2024
https://www.organigram.ca/press-releases/organigram-receives-health-canadas-final-redetermination-on-jolts
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 6 months ago
OGI~Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty ~ February 28th, 2024OGI~
https://www.organigram.ca/press-releases/organigram-applauds-the-standing-committee-on-finances-recommendation-on-excise-1
👍️ 2 💚 2 💱 1 💲 1 🚀 1
Hunchbackgeek Hunchbackgeek 7 months ago
Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty
February 28th, 2024

https://www.organigram.ca/press-releases/organigram-applauds-the-standing-committee-on-finances-recommendation-on-excise-1


Revised Excise Framework Remains One of the Most Critical Reforms Required to Ensure the Long-Term Viability of the Cannabis Industry

Toronto, Ontario – February 28, 2024 - Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) enthusiastically supports the Standing Committee on Finance’s recent recommendation on the Excise Duty framework.

In a recently released report, titled ‘Shaping our Economic Future: Canadian Priorities,’ the House of Commons Standing Committee on Finance has unanimously recommended adjusting the excise duty formula for cannabis so that it is limited to a 10% ad valorem rate, and modifying the duty's operation, including applying excise stamps on cannabis products.

Based on a survey conducted by the Cannabis Council of Canada, licensed producers currently pay up to 35% of top-line revenue in excise duties because of an erroneous assumption at the time of legalization that the price of cannabis flower would be approximately $10 per gram to the retail consumer. In reality, the price per gram of cannabis flower has fallen to as low as approximately $3 per gram, limiting cannabis companies’ ability to remain competitive on pricing, invest in innovation, retain jobs, and ultimately support the government’s stated objectives of illicit market conversion and promoting public health and safety.

“The pre-budget recommendation could not have come at a better time.” said Beena Goldenberg, CEO of Organigram. “Excise reform is critical to the long-term viability of the Canadian cannabis industry. The positive impact of the proposed reduction to a 10% ad valorem rate on the sustainability of the sector cannot be underestimated. We sincerely hope that the recommendation made by the Finance Committee is adopted by the Federal, Provincial and Territorial governments so that Canada can retain its position as global leader in the emerging cannabis movement.”

“We are also encouraged by recent reports indicating that the CRA is taking proactive measures to level the playing field by collecting more diligently from LPs who have fallen behind on their remittances for excise duties”, added Beena.

About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include adoption of budget recommendations and timing thereof, changes to market conditions, consumer preferences and regulatory climate and factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.


For Media enquiries:

Megan McCrae
Senior Vice President, Global Brands and Corporate Affairs
megan.mccrae@organigram.ca
Organigram
👋 2 👍️ 2 💚 2 💯 2 🤑 2
Hunchbackgeek Hunchbackgeek 7 months ago
It's reall it's on their Website. I'll post it as well. Thank you Bazwar6. 😉
👍️ 2 💚 2 💯 2 😎 2 🤑 2
Bazwar6 Bazwar6 7 months ago
If this happens this is great news for Canadian LPs

https://www.businesswire.com/news/home/20240228644763/en/Organigram-Applauds-the-Standing-Committee-on-Finance’s-Recommendation-on-Excise-Duty
👍️ 2 💚 1 🤑 1
WALL STREET KID WALL STREET KID 7 months ago
That's awesome thanks bud
🇮🇩 1 🇮🇴 1 🇹🇹 1 👍️ 1 💚 1 💯 1 😎 1 🤑 1
Hunchbackgeek Hunchbackgeek 7 months ago
OGI~Organigram Reports First Quarter Fiscal 2024 Results https://www.organigram.ca/press-releases/organigram-reports-first-quarter-fiscal-2024-results

Achieved positive cash flow from operations, solidified #2 market position in Canada among licensed producers, significantly improved margins sequentially quarter-over-quarter, and closed first $41.5 million tranche of previously announced $124.6 million investment from BAT
👍️ 2 💚 1 💯 1 💹 1 🚀 2
WALL STREET KID WALL STREET KID 7 months ago
Thanks for the update Hunchbackgeek
👍️ 1 💚 1
Bazwar6 Bazwar6 7 months ago
https://www.marketwatch.com/story/organigram-shares-fall-on-loss-revenue-miss-as-international-sales-lag-in-1q-b9d4779a
👍️0
Hunchbackgeek Hunchbackgeek 7 months ago
OGI~Organigram to Report First Quarter Fiscal 2024 Results on February 13, 2024
February 7th, 2024

https://investors.organigram.ca/press-releases/organigram-to-report-first-quarter-fiscal-2024-results-on-february-13-2024
👍️ 2 💚 1
Hunchbackgeek Hunchbackgeek 7 months ago
OGI~Organigram Completes First Shipment to Germany, Extending its International Reach

January 31st, 2024

https://investors.organigram.ca/press-releases/organigram-completes-first-shipment-to-germany-extending-its-international-reach
👍️ 2 💚 1
Hunchbackgeek Hunchbackgeek 7 months ago
OGI Happy New Year to you! Super to hear from you John! OGI Always surprises me. It's a good company. We'll see, yes, I still have my shares too, so does our friend. 😎
👍️ 2 💚 1
Bazwar6 Bazwar6 7 months ago
https://www.investorsobserver.com/news/stock-update/organigram-holdings-inc-ogi-stock-adds-26-99-this-week-should-you-buy
👍️ 2 💚 1
john1311 john1311 7 months ago
Happy new year Hunch.... isn't it time this sector awakens again...? I've still a few thousand shares in OGI... I did so well with OGI that I had to hold some shares through the bad times because of my fondness for this company... now, isn't it time OGI enjoys its bright future...
👍️ 2 😎 1
Bazwar6 Bazwar6 7 months ago
Brings back good memories
👍️ 1
mte1955 mte1955 7 months ago
Haven't seen this in a while...YAY!
👍️ 1
Hunchbackgeek Hunchbackgeek 8 months ago
OGI Excellent! Thank you WeedIsGreen!
👍️ 2 💚 1

Your Recent History

Delayed Upgrade Clock